Company intelligence / Profile preview

Balanced Pharma

Cornelius, North Carolina, USAbalanced.network ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Balanced Pharma has developed two main products: BPI-001 ("Libracaine"), a next-generation injectable dental anesthetic designed to be less painful and more effective than current options, and BPI-004 ("Enduracaine"), a non-opioid injectable analgesic providing up to three days of post-surgical pain relief. Both products are positioned as best-in-class with improved patient comfort. The company has raised over $10 million in funding and secured strategic investment from Septodont—a global leader in dental anesthetics—who also joined their board. Additional patents have been granted for their cartridge technology.

Therapeutic areas: Other
Modalities: Small molecule (local anesthetics)Non-opioid analgesic
Industry: Biotech

Partnerships

Septodont

Beyond the preview

Go deeper on Balanced Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Balanced Pharma.

Explore the full profile